iBio, Inc. Share Price
NASDAQ: IBIO | Micro CapiBio, Inc. Stock Performance
Open $1.41 | Prev. Close $1.39 | Circuit Range N/A |
Day Range $1.38 - $1.42 | Year Range $0.58 - $3.76 | Volume 38,339 |
Average Traded $1.40 |
iBio, Inc. Share Price Today
As of 9 August 2026, iBio, Inc.'s share price is $1.42. The stock opened at $1.41, compared to its previous close of $1.39. During today's trading session, iBio, Inc.'s share price traded between $1.38 and $1.42, with an average price of $1.40. Over the past 52 weeks, the stock has recorded a high of $3.76 and a low of $0.58. In terms of performance, iBio, Inc.'s share price has declined by 50.09% over the last six months and is up 74.69% on a year-on-year basis.
iBio, Inc. Share Price Chart
iBio, Inc. Stock Fundamentals & Key Indicators
Market Cap $14.86M | PE Ratio (TTM) -0.81 | Dividend Yield N/A |
EPS (TTM) $-1.75 | Revenue (TTM) $400000.00 | Return On Equity (TTM) -123.50% |
Profit Margin -4594.25% | Debt to Equity 0.41 | Quarterly Earnings Growth YoY -106.07% |
iBio, Inc. Quarterly Profit & Loss
All figures in USD
iBio, Inc. Annual Profit & Loss
All figures in USD
About iBio, Inc.
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
iBio, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $1.42 | $1.42 | +0.35% |
Jul 2026 | $1.77 | $1.41 | -19.20% |
Jun 2026 | $1.91 | $1.75 | -8.40% |
May 2026 | $1.62 | $1.91 | +12.06% |
Apr 2026 | $1.96 | $1.70 | -10.99% |
Mar 2026 | $2.56 | $1.91 | -32.63% |
Feb 2026 | $2.06 | $2.83 | +34.04% |
Jan 2026 | $1.93 | $2.12 | +8.46% |
Dec 2025 | $1.19 | $1.95 | +59.18% |
Nov 2025 | $1.65 | $1.23 | -23.20% |
Oct 2025 | $0.81 | $1.59 | +99.13% |
Sep 2025 | $0.77 | $0.80 | -1.11% |
IBIO Share Price FAQs
What is iBio, Inc. share price today?
What is the 52 week high and 52 week low of iBio, Inc. stock?
What is IBIO's market capitalisation today?
What is IBIO's net income for the last quarter?
What is the 5 year returns of IBIO?
What is the high & low stock price of IBIO today?
Can I buy IBIO shares in India?